Venus Metals Corporation Limited logo

Venus Metals Corporation Limited (VMC)

Market Open
ASX ASX
52.6M Market Cap
- P/E Ratio
- Div Yield
3.04M Volume
- Eps
Want to track VMC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

VMC pays dividends to its shareholders, with the most recent payment made on Jul 30, 2019. The next estimated payment will be in 30 Jul 2019 on Jul 30, 2019 for a total of A$0.00054.
The last earnings report, released on Mar 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

Venus Metals Corporation Limited (VMC) FAQ

On which exchange is it traded?

Venus Metals Corporation Limited is listed on ASX.

What is its stock symbol?

The ticker symbol is VMC.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 52.6M.

Has Venus Metals Corporation Limited ever had a stock split?

No, there has never been a stock split.

Venus Metals Corporation Limited Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Mr. Matthew Vernon Hogan M.A.I.C.D. CEO
ASX Exchange
AU000000VMC0 ISIN
AU Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Episurf Medical AB (publ) is a pioneering medical device company with a global reach, having a significant presence in Germany, Sweden, across Europe, the United States, and other international markets. Established in 2008 and originally named Diamorph Medtech AB before rebranding in 2010, the company has carved out a niche in the medical industry by focusing on designing and manufacturing advanced implants and surgical instruments. With its headquarters located in Stockholm, Sweden, Episurf Medical is at the forefront of offering innovative solutions aimed at improving the quality of life for patients suffering from joint issues, focusing on the knee, ankle, and potentially extending to the big toe. Through a blend of cutting-edge technology and personalized medical devices, the company is driving forward the fields of orthopedics and personalized medicine.

Products and Services

Episealer Knee: A cutting-edge implant designed for repairing focal cartilage and bone defects in the knee joint. It aims to reduce pain and increase mobility, offering a personalized fit to the patient's anatomy and the size of the lesion.

Episealer Patellofemoral System: This system targets osteoarthritis limited to the patellofemoral part of the knee joint, providing a tailored solution designed to offer relief and improve function in this specific area.

Episealer Talus: Focused on the ankle joint, this implant addresses bone and cartilage defects in the talus bone, providing a new treatment avenue for patients with injuries in this less commonly addressed area.

Epioscopy: A diagnostic tool developed to vividly identify and visualize femoral knee joint cartilage and bone lesions, including defects on the cruciate ligaments and menisci. This technology aims to enhance surgical planning and outcomes by providing clear imaging of the affected areas.

Epiguide: A surgical drill guide that complements the Episealer implants, ensuring precise and accurate implant placement, thereby enhancing the success rate of surgeries.

µiFidelity: An innovative web platform that streamlines order management, communication, personalized implant design, and surgical pre-planning, ensuring each patient's treatment is as unique as their diagnosis.

Episealer MTP implant: Currently in development, this implant is designed for the treatment of the metatarsophalangeal (MTP) joint in the big toe, promising a significant advancement in foot surgery.

Talus Osteotomy Guide (TOG): A bespoke guide that assists in surgeries involving the distal tibia, crafted using CT and MRI images for a perfect fit and optimal surgical outcomes.

MRI protocol: This proprietary protocol ensures correct assessment of damage, enabling 3D visualization and precise device design, which is crucial for successful patient-specific treatments.

Damage Marking Report (DMR): A detailed visualization tool that outlines the joint surface and underlying bone defects, aiding in the selection of the most effective treatment for the patient.

Contact Information

Address: 8 Alvan Street, Subiaco, WA, Australia, 6008
Phone: 61 8 9321 7541